Elimination of Schistosoma mansoni in infected mice by slow release of artemisone

Daniel Gold, Mohammed Alian, Avraham Domb, Yara Karawani, Maysa Jbarien, Jacques Chollet, Richard K. Haynes, Ho Ning Wong, Viola Buchholz, Andreas Greiner, Jacob Golenser

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


The current treatment of schistosomiasis is based on the anti-helminthic drug praziquantel (PZQ). PZQ affects only the adult stages of schistosomes. In addition, resistance to PZQ is emerging. We suggest a drug, which could serve as a potential alternative or complement to PZQ, and as a means of treating infections at earlier, pre-granuloma stage. Derivatives of the peroxidic antimalarial drug artemisinin have been indicated as alternatives, because both plasmodia and schistosomes are blood-feeding parasites. The mechanism of action of artemisinins is related to oxidative effects of the artemisinins on intracellular reductants leading to formation of cytotoxic reactive oxygen species. We used artemisone, which has improved pharmacokinetics and anti-plasmodial activity, and reduced toxicity compared to other artemisinins in clinical use against malaria. We infected adult mice by subcutaneous injection of S. mansoni cercariae (about 200) and treated them at various times post infection by the following methods: i. artemisone suspension administered by gavage (400–450 mg/kg); ii. subcutaneous injection of a gel containing a known concentration of artemisone (115–120 mg/kg); iii. subcutaneous insertion of the drug incorporated in a solid polymer (56–60 mg/kg); iv. intraperitoneal injection of the drug solubilized in DMSO (115–120 mg/kg). Drug administration in polymers was performed to enable slow release of the artemisone that was verified in vivo and in vitro bioassays using drug-sensitive malaria parasites. We found superior strong anti-schistosome effects up to a total reduction of worm number, mainly following repetitive treatments with the drug absorbed in the polymers (73.1% and 95.9% reduction in mice treated with artemisone in gel 7 and 14, and 21, 28 and 35 days post infection, respectively). The results indicate that artemisone has a potent anti-schistosome activity. Its main importance in this context is its effectiveness in treating hosts harboring juvenile schistosomes, before egg-deposition and induction of deleterious immune responses.

Original languageEnglish
Pages (from-to)241-247
Number of pages7
JournalInternational Journal for Parasitology: Drugs and Drug Resistance
Issue number2
StatePublished - 1 Aug 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017


We thank Cipla for the kind donation of artemisone and the DFG for financial support. RKH acknowledges support from the South African Medical Research Council (MRC) with funds from the National Treasury under its Economic Competitiveness and Support Package. The South African National Research Foundation is thanked for financial support to RKH.

FundersFunder number
Medical Research Council
South African Medical Research Council
Deutsche Forschungsgemeinschaft
National Research Foundation of Korea


    • Artemisone
    • Schistosoma
    • Slow release
    • Treatment


    Dive into the research topics of 'Elimination of Schistosoma mansoni in infected mice by slow release of artemisone'. Together they form a unique fingerprint.

    Cite this